Premium
A systematic review of patient preference elicitation methods in the treatment of colorectal cancer
Author(s) -
Currie A.,
Askari A.,
Nachiappan S.,
Sevdalis N.,
Faiz O.,
Kennedy R.
Publication year - 2015
Publication title -
colorectal disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.029
H-Index - 89
eISSN - 1463-1318
pISSN - 1462-8910
DOI - 10.1111/codi.12754
Subject(s) - medicine , colorectal cancer , cinahl , medline , life expectancy , quality of life (healthcare) , cochrane library , psycinfo , systematic review , intensive care medicine , preference , cancer , surgery , psychological intervention , randomized controlled trial , population , nursing , environmental health , microeconomics , political science , law , economics
Aim This systematic review aimed to assess the use of patient preference in colorectal cancer treatment. Eliciting patient preference is important for shared decision‐making in colorectal cancer treatment. The introduction of newer treatments, which balance quality of life and overall survival, makes this an important future focus. Method A systematic search strategy of MEDLINE , Embase, Psyc INFO , CINAHL and the Cochrane Database for Systematic Reviews was undertaken to obtain relevant articles. Information regarding the type of patients included, preference instruments, study settings, outcomes and limitations was extracted. Results The eight articles comprising this review each described an empirical study using a validated instrument to define patient preference for an aspect of colorectal cancer treatment. The evidence suggests that patients are prepared to trade significant reductions in life expectancy to avoid certain complications of colorectal surgery, particularly stoma formation. In the adjuvant setting, patients are prepared to risk significant treatment side effects to gain small potential increases in life expectancy and chance of survival. Where neoadjuvant or adjuvant treatment risks worsening function, however, patients generally forgo any potential increase in survival to improve bowel function and therefore quality of life. The only predictors of preference were tertiary education and previous cancer treatment. Conclusion Most patients judge a moderate survival benefit to be sufficient to make adjuvant therapy for colorectal cancer worthwhile, but they are willing to trade a potential reduction in life expectancy and survival to avoid certain unwanted surgical sequelae.